136 related articles for article (PubMed ID: 31695173)
21. Brentuximab vedotin prior to allogeneic stem cell transplantation in Hodgkin lymphoma: a report from the EBMT Lymphoma Working Party.
Bazarbachi A; Boumendil A; Finel H; Mohty M; Castagna L; Peggs KS; Blaise D; Afanasyev B; Diez-Martin JL; Sierra J; Bloor A; Martinez C; Robinson S; Malladi R; El-Cheikh J; Corradini P; Montoto S; Dreger P; Sureda A
Br J Haematol; 2018 Apr; 181(1):86-96. PubMed ID: 29468647
[TBL] [Abstract][Full Text] [Related]
22. Controversies in autologous and allogeneic hematopoietic cell transplantation in peripheral T/NK-cell lymphomas.
Shustov A
Best Pract Res Clin Haematol; 2013 Mar; 26(1):89-99. PubMed ID: 23768643
[TBL] [Abstract][Full Text] [Related]
23. [Outcomes of 33 patients with anaplastic large cell lymphoma treated after hematopoietic stem cell transplantation].
Lu N; Li XF; Dong YJ; Wang YN; Fu XR; Wu YM; Li YH; Wang MH; Li NN; Ren HY; Wang Z; Zhang MZ; Wu XX; Hu LD; Liu Y; Huang WR
Zhonghua Xue Ye Xue Za Zhi; 2020 Feb; 41(2):117-122. PubMed ID: 32135627
[No Abstract] [Full Text] [Related]
24. Brentuximab vedotin as salvage treatment in Hodgkin lymphoma naïve transplant patients or failing ASCT: the real life experience of Rete Ematologica Pugliese (REP).
Pavone V; Mele A; Carlino D; Specchia G; Gaudio F; Perrone T; Mazza P; Palazzo G; Guarini A; Loseto G; Eleonora P; Cascavilla N; Scalzulli P; Melpignano A; Quintana G; Di Renzo N; Tarantini G; Capalbo S
Ann Hematol; 2018 Oct; 97(10):1817-1824. PubMed ID: 30054707
[TBL] [Abstract][Full Text] [Related]
25. The European Medicines Agency Review of Brentuximab Vedotin (Adcetris) for the Treatment of Adult Patients With Relapsed or Refractory CD30+ Hodgkin Lymphoma or Systemic Anaplastic Large Cell Lymphoma: Summary of the Scientific Assessment of the Committee for Medicinal Products for Human Use.
Gravanis I; Tzogani K; van Hennik P; de Graeff P; Schmitt P; Mueller-Berghaus J; Salmonson T; Gisselbrecht C; Laane E; Bergmann L; Pignatti F
Oncologist; 2016 Jan; 21(1):102-9. PubMed ID: 26621039
[TBL] [Abstract][Full Text] [Related]
26. Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed/refractory Hodgkin lymphoma: an analysis of the Lymphoma Working Party of the EBMT.
Sureda A; Genadieva Stavrik S; Boumendil A; Finel H; Khvedelidze I; Dietricht S; Dreger P; Hermine O; Kyriakou C; Robinson S; Schmitz N; Schouten HC; Tanase A; Montoto S
Bone Marrow Transplant; 2020 Nov; 55(11):2170-2179. PubMed ID: 32415225
[TBL] [Abstract][Full Text] [Related]
27. [Successful bridging therapy with alectinib prior to allogeneic stem cell transplantation for refractory ALK-positive anaplastic large cell lymphoma].
Kono A; Tanaka K; Shimada T; Bando K; Takahata A; Koi S; Yamamoto M; Mori T; Toyota S
Rinsho Ketsueki; 2024; 65(3):158-163. PubMed ID: 38569859
[TBL] [Abstract][Full Text] [Related]
28. Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.
Laport GG; Wu J; Logan B; Bachanova V; Hosing C; Fenske T; Longo W; Devine SM; Nademanee A; Gersten I; Horowitz M; Lazarus HM; Riches ML;
Biol Blood Marrow Transplant; 2016 Aug; 22(8):1440-1448. PubMed ID: 27118571
[TBL] [Abstract][Full Text] [Related]
29. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed/refractory Hodgkin's lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.
Genadieva-Stavrik S; Boumendil A; Dreger P; Peggs K; Briones J; Corradini P; Bacigalupo A; Socié G; Bonifazi F; Finel H; Velardi A; Potter M; Bruno B; Castagna L; Malladi R; Russell N; Sureda A
Ann Oncol; 2016 Dec; 27(12):2251-2257. PubMed ID: 28007754
[TBL] [Abstract][Full Text] [Related]
30. Brentuximab vedotin prior to allogeneic stem cell transplantation increases survival in chemorefractory Hodgkin's lymphoma patients.
Gaudio F; Mazza P; Mele A; Palazzo G; Carella AM; Delia M; Pisapia G; Pastore D; Cascavilla N; Pavone V; Specchia G
Ann Hematol; 2019 Jun; 98(6):1449-1455. PubMed ID: 30868307
[TBL] [Abstract][Full Text] [Related]
31. Impact of Pretransplant Salvage Therapies on Outcome of Hodgkin Lymphoma Patients Performing Allogeneic Transplant.
Fanelli F; Hohaus S; Cantonetti M; Cimino G; Pennese E; Battistini R; Galli E; Cerretti R; Proia A; Fatone F; Provenzano I; Abruzzese E; Finolezzi E; Pulsoni A; Rigacci L
Chemotherapy; 2023; 68(3):131-137. PubMed ID: 36549287
[TBL] [Abstract][Full Text] [Related]
32. Salvage treatment for relapsed/refractory Hodgkin lymphoma: role of allografting, brentuximab vedotin and newer agents.
Martino M; Festuccia M; Fedele R; Console G; Cimminiello M; Gavarotti P; Bruno B
Expert Opin Biol Ther; 2016; 16(3):347-64. PubMed ID: 26652934
[TBL] [Abstract][Full Text] [Related]
33. [Allogeneic hematopoietic stem cell transplantation following treatment with brentuximab vedotin for refractory Hodgkin lymphoma].
Yamane Y; Koda Y; Kohashi S; Kato J; Hashida R; Sakurai M; Toyama T; Kikuchi T; Okayama M; Kasahara H; Karigane D; Shimizu T; Okamoto S; Mori T
Rinsho Ketsueki; 2017; 58(7):755-759. PubMed ID: 28781270
[TBL] [Abstract][Full Text] [Related]
34. [Salvage Trerapy for Patients with Relapsed and Refractory Lymphoma by Allogeneic Hematopoietic Stem Cell Transplantation].
Yin Y; Qiu ZX; Li Y; Xu WL; Sun YH; Liu W; Wang WS; Wang MJ; Wang LH; Dong YJ; Ou JP; Cen XN; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Apr; 25(2):418-425. PubMed ID: 28446286
[TBL] [Abstract][Full Text] [Related]
35. Analysis of relapse after transplantation in acute leukemia: A comparative on second allogeneic hematopoietic cell transplantation and donor lymphocyte infusions.
Ortí G; Sanz J; García-Cadenas I; Sánchez-Ortega I; Alonso L; Jiménez MJ; Sisinni L; Azqueta C; Salamero O; Badell I; Ferra C; de Heredia CD; Parody R; Sanz MA; Sierra J; Piñana JL; Querol S; Valcárcel D
Exp Hematol; 2018 Jun; 62():24-32. PubMed ID: 29526774
[TBL] [Abstract][Full Text] [Related]
36. Survival after autologous versus allogeneic transplantation in patients with relapsed and refractory Hodgkin lymphoma.
Fakhri B; Yilmaz E; Gao F; Ambinder RF; Jones R; Bartlett NL; Cashen A; Wagner-Johnston N
Leuk Lymphoma; 2021 Oct; 62(10):2408-2415. PubMed ID: 33988071
[TBL] [Abstract][Full Text] [Related]
37. Population-based cohort study of the efficacy of brentuximab vedotin in relapsed systemic anaplastic large-cell lymphoma using Public Health England data.
Halligan SJ; Grainge MJ; Martinez-Calle N; Fox CP; Bishton MJ
Br J Haematol; 2022 Feb; 196(4):932-938. PubMed ID: 34664265
[TBL] [Abstract][Full Text] [Related]
38. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin's lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study.
Locatelli F; Mauz-Koerholz C; Neville K; Llort A; Beishuizen A; Daw S; Pillon M; Aladjidi N; Klingebiel T; Landman-Parker J; Medina-Sanson A; August K; Sachs J; Hoffman K; Kinley J; Song S; Song G; Zhang S; Suri A; Gore L
Lancet Haematol; 2018 Oct; 5(10):e450-e461. PubMed ID: 30290902
[TBL] [Abstract][Full Text] [Related]
39. Long-term remission of primary refractory ALK-positive anaplastic large cell lymphoma after allogeneic hematopoietic stem cell transplantation.
Miyazaki M; Ichikawa S; Onishi Y; Fukuhara N; Furukawa E; Onodera K; Yokoyama H; Ichinohasama R; Harigae H
J Clin Exp Hematop; 2022 Sep; 62(3):164-168. PubMed ID: 35732409
[TBL] [Abstract][Full Text] [Related]
40. Allogeneic stem cell transplantation using lymphoablative rather than myeloablative conditioning regimen for relapsed or refractory lymphomas.
Yoon JH; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Kim HJ; Min CK; Lee JW; Min WS; Cho SG
Hematol Oncol; 2017 Mar; 35(1):17-24. PubMed ID: 25782369
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]